The stock has touched a high at Rs. 1,977 in early morning deals on the BSE.
According to media reports, Lupin has received approval from the US Food & Drug Administration (US FDA) for diabetes drug PrandiMet.
The stock climbed to a high of Rs. 1,977, and is now up almost a percent at Rs. 1,973.
The counter has seen trades of around 8,553 shares as against the two-week daily average volume of 55,000 shares.
Meanwhile, the BSE Sensex is up 85 points at 28,531.
No comments:
Post a Comment